BiPar Sciences, Inc.

EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI) announces that Director Sunil Patel passed away suddenly last week. The Board of Directors and leadership of OmniAb extend their deepest condolences to those who loved and cared for Sunil and express their gratitude for Sunil’s many contributions to OmniAb. Sunil Patel was appointed to OmniAb’s Board in November 2022 when OmniAb was spun-out of Ligand Pharmaceuticals as an independent, publicly-traded company, and previously served on the Ligand Pharmaceuticals Board of Directors since 2010. “It is with profound sadness that we announce Sunil’s passing,” said John Higgins, OmniAb Board Chair. “Sunil was a highly-valued and engaged member of the OmniAb Board of Directors and played an important role driving our investments and strategy. Above that, he was a friend and colleague for the past two decades. He will be remembered by all who had the pleasure of working with him as a very thoughtful business operator, strongly devoted to cutting-edge science supporting medical research. He was kind and gentle, and an independent thinker who brought levity and joy to any meeting or encounter. Sunil’s support for antibody discovery research and the formation of OmniAb are among his most important business contributions. He saw the future of where the field was going and at every turn helped to drive our strategy. He will be remembered by those who had the pleasure of knowing him as a warm and incredibly bright individual of high integrity. For all who knew Sunil, we will honor his legacy as we advance our work.” With more than 25 years of senior management and R&D experience in the biotechnology industry, Mr. Patel most recently worked as an independent consultant to biotechnology companies advising on strategy and corporate development initiatives. Previously, he served in executive roles at OncoMed Pharmaceuticals, Inc., including Executive Vice President and Chief Financial Officer. He held senior management positions in corporate development, marketing and strategy with BiPar Sciences, Inc., Allos Therapeutics, Inc., Connetics, Abgenix, Inc. and Gilead Sciences Inc. Early in his career Mr. Patel worked at McKinsey & Company serving biotechnology and pharmaceutical clients, and held scientific research positions at ZymoGenetics, Inc. and ProCyte Corporation. He received an undergraduate degree in chemistry from the University of California, Berkeley and a master’s degree in molecular bioengineering/biotechnology from the University of Washington. About OmniAb® OmniAb’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence™ (BI) of our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic® (transgenic rat) and OmniClic® (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur™ features unique structural attributes of cow antibodies for complex targets. We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies with superior performance and developability characteristics. These proprietary technologies are joined with and leverage OmniDeep, which is a suite of in silico tools for therapeutic discovery and optimization that are woven throughout OmniAb’s various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many emerging target classes. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others. The OmniAb suite of technologies span from BI-powered repertoire generation to cutting-edge antibody discovery and optimization offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit . View source version on businesswire.com: Contacts OmniAb, Inc. Neha Singh, Ph.D. investors@OmniAb.com Twitter (X) @OmniAbTech (510) 768-7760 Source: OmniAb, Inc. View this news release online at:

July 12, 2016 By Mark Terry , BioSpace.com Breaking News Staff It’s not exactly a secret that Paris-based Sanofi is on the prowl for acquisitions to bolster its sagging oncology portfolio. It’s ongoing hostile takeover for the Bay Area’s Medivation is the prime example. The company’s chief scientific officer, Gary Nabel , recently provided some granularity to Sanofi’s interests. He noted to Bloomberg that the French company is looking for approved cancer drugs as well as experimental ones that use new knowledge or techniques. Medivation fits both of those, with its blockbuster Xtandi for prostate cancer, and a PARP inhibitor, talazoparib, in late stage trials for breast cancer patients with BRCA mutations. “One part of the approach is to take mature assets and to maximize value from those,” Nabel told Bloomberg. “Those are late-stage acquisitions. But equally important, it’s looking at early stage developments like PARP inhibitors and others.” Sanofi’s oncology presence has but hurt by patent expirations and generic competition. It also had a notable failure when it acquired the Bay Area’s BiPar Sciences in 2009. The drug it picked up in the deal, BSI-201, didn’t meet its endpoints in 2011. Then the company made a strategic decision that made sense at the time, but didn’t pan out. While many companies began to look at immuno-oncology, such as Merck & Co. and Bristol-Myers Squibb , Sanofi focused on targeted cancer therapies. The poster child for that type of work is Novartis AG ’s Gleevec. Although Gleevec was enormously successful, even revolutionary, that type of work has proven to be a challenge with only a handful of successes. “Unless you were very lucky, and had a very good understanding of the target that you were after in the individual patient,” Nabel told Bloomberg, “the success more broadly was going to be limited.” Perhaps a step too slow, Sanofi tossed $2.2 billion into a deal with Regeneron Pharmaceuticals to push into immuno-oncology, specifically on checkpoint inhibitors targeting PD-1. The two companies have done okay with their new cholesterol medicine, Praluent, progress in cancer has been harder to see. Although an acquisition of Medivation still seems likely, there are hints that Sanofi may be interested in other oncology companies as well. Nabel didn’t provide any specifics, but did say, “There’s innovation externally—late stage, where you pay more, but you get something that’s more defined. Early stage, where you pay less, and you take on more risk. But you can potentially pick up very transformative ideas early on. So we’d like to sample across that whole spectrum.” Others have noted that Sanofi has an interest in the rare disease market as well, and that Vertex Pharmaceuticals and Alexion Pharmaceuticals might be interesting targets. Vertex markets Kalydeco and Orkambi for cystic fibrosis (CF), and has nine pipeline candidates in CF and cancer. Alexion’s focus is rare diseases, with three approved drugs, Sliris to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), Strensiq to treat hypophosphatasia (HPP) and Kanuma to treat lysosomal acid lipase deficiency (LAL-D). Its pipeline is focused on various areas, including hematology, neurology, nephrology, metabolic disorders and inflammatory diseases. There have also been rumors that if the Medivation deal falls through, Sanofi might go go after Novato, California-based BioMarin Pharmaceutical , best known for its failed Duchenne muscular dystrophy drug, Kyndrisa (drisapersen). If it is interested in BioMarin, it would be for rare genetic diseases, which include a pipeline for achondroplasia, CLN2 disease, Hemophilia A and Sanfilippo Syndrome. Already marketed drugs include Vimizim for Morquio A Syndrome, Kuvan for PKU, Naglazyme for MPS VI, Aldurazyme for MPS I, and Firdapse for LEMS.

PARIS and SOUTH SAN FRANCISCO, Calif., July 17, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) and its wholly owned subsidiary, BiPar Sciences, today announced the initiation of the pivotal Phase 3 trial for BSI-201 in combination with chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC), defined by tumors lacking expression of estrogen, progesterone receptors and without over-expression of HER2. BSI-201 is a novel, investigational, targeted therapy which inhibits poly (ADP-ribose) polymerase (PARP1), an enzyme involved in DNA damage repair.